MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,287 INR | -1.22% |
|
-3.47% | +15.35% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
Sector
Pharmaceuticals
Calendar
2024-05-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,287
INR
Average target price
2,186
INR
Spread / Average Target
-4.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.35% | 11.12B | |
| +31.52% | 662B | |
| +21.96% | 546B | |
| -5.21% | 359B | |
| +17.02% | 323B | |
| +5.01% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.98% | 167B |
- Stock Market
- Equities
- MANKIND Stock
- News Mankind Pharma Limited
- CARE Gives AA+ Rating to Mankind Pharma's Long-term Bank Financing; Outlook Stable